The Nomination Committee’s proposal for the Board of Directors of Xspray Pharma AB

Press release 2022-04-19

The Nomination Committee proposes Robert Molander as a new member of the Board of Directors at the Annual General Meeting.

The Nomination Committee proposes that members of the Board of Directors Anders Ekblom (Chairman since 2021), Anders Bladh (member since 2021), Maris Hartmanis (member since 2015), Torbjörn Koivisto (member since 2017), Christine Lind (member since 2019) and Carl-Johan Spak (member since 2015) are to be re-elected at the Annual General Meeting held on May 19, 2022. Gunnar Gårdemyr (member since 2019), has declined reelection.

Information about the board members proposed for re-election is available on the company's website, as well as in the company's annual report for 2021.

The Nomination Committee proposes Robert Molander to be elected as new member of the Board of Directors.

Robert Molander is a dual citizen of the Unites States and Sweden and lives primarily in the United States. He holds an MBA from the University of Washington in Marketing and Finance as well as two bachelor's degrees from Miami University in Economics and International Studies. Robert Molander has 25 years of experience working in life science organizations with the commercialization of pharmaceuticals in the United States and has also served as an Executive Council Member at Harvard Medical School. A selection of the organizations that Robert Molander has worked for include Novartis, Pfizer and Trialbee. Robert Molander is also a board member of Infant Bacterial Therapeutics AB (publ), listed at Nasdaq Stockholm.

Xspray Pharma's Nomination Committee consists of Gillis Cullin, appointed by the Baltic Sea Foundation, Anders Bladh appointed by Ribbskottet AB, Caroline Sjösten, appointed by Swedbank Robur Fonder, Jannis Kitsakis, appointed by AP4, and by Anders Ekblom, Chairman of the Board, Xspray Pharma AB.

For further information, please contact:

Christina Malmberg Hägerstrand
Senior Vice President Communications & Investor Relations
+46 72 855 93 29
christina.malmberg.hagerstrand@xspray.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs of PKIs already marketed for the treatment of cancer, which numbered to 72 in the end of 2021. The company’s leading product candidates, Dasynoc (former HyNap-Dasa), HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com